Jumbo Supermarkten Selects Quintiq to Optimize its Complex Supply Chain
Quintiq, a Dassault Systèmes company and global leader in supply chain planning and optimization (SCP&O), announces that it has been selected to further optimize Jumbo Supermarkten’s supply chain. The fastest growing supermarket chain in the Netherlands, Jumbo is on a mission to provide outstanding service and products at the lowest prices, exceeding customer expectations every day.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180313005702/en/
Supermarket chain Jumbo selects Quintiq to optimize end-to-end supply chain (Photo: Business Wire)
This mission is well supported by Quintiq’s optimization technology. The Quintiq solution will efficiently plan Jumbo’s transport and warehouse capacities. Jumbo’s supply chain involves 10 distribution centers, almost 600 stores and about 500 owned and chartered trucks. The scope covers the planning of store distribution, home deliveries, inbound operations, backhauls for all channels and logistics between distribution centers. With a planning solution that integrates with existing systems, Jumbo will gain full transparency of its supply chain.
“We’ve found the right technology partner to help us plan and control our supply chain,” said Karel de Jong, director of supply chain at Jumbo. “Quintiq provides us with integrated supply chain management, an approach that is demand-driven and optimized based on Jumbo’s business goals and constraints.”
There’s a wide range of other requirements and constraints that comes with supply chain planning. The Quintiq solution is intelligent enough to take them into account while improving Jumbo’s delivery performance, cost savings and planning flexibility. Jumbo’s constraints include store opening times, specific timeframes for deliveries, amount of employees and shifts and different temperature compartments in vehicles. The solution will also take into account regulatory constraints such as restrictions when transporting fresh produce, as well as legal rules in terms of truck drivers’ working hours. With Quintiq’s optimized planning, Jumbo will be able to achieve more sustainable operations through reducing their carbon footprint.
The solution will be used for Jumbo’s logistics planning on tactical, operational and day-of-execution levels. Using scenario-based tactical planning, Jumbo will be able to evaluate all possible options against specific KPIs. For operational planning, Quintiq takes into account the latest order volume and resource capacity for optimized plans up to one week ahead. On the day of execution, the solution ensures smooth-running movements based on confirmed orders and supports planners in managing disruptions effectively. The latter is enabled by real-time monitoring of execution, which provides visibility of both resources and charter resources in terms of trip progress, traffic and disruptions.
“Jumbo has a large, complex supply chain that's rapidly growing. Optimized planning is key to reaching its full potential,” said Rob van Egmond, CEO at Quintiq. “This is where Quintiq comes in. We’re able to provide real-time insights that help Jumbo make the right logistics decisions swiftly. This enables Jumbo to improve on-shelf availability and increase customer satisfaction.”
About Jumbo Supermarkten
Jumbo currently has over 580 shops, of which three are food markets. Additionally, the supermarket chain has 390 pick-up points for online orders and a home delivery service. The unique Jumbo formula (best service with largest assortment at lowest prices) applies to all of its shops and online store. Customers can rely on Jumbo’s brand promise of 7 Certainties. By putting the customer at the heart of its business, the family-owned company has become one of the fastest growing supermarkets in the Netherlands. After taking over Super de Boer in 2009 and C1000 in 2012, Jumbo became the second largest grocery chain in the country. Additionally, Jumbo took over the La Place restaurant chain in 2016.For more information, visit jumbo.com.
Every business has its supply chain planning challenges. Some of those challenges are large, some are complex and some seem impossible to solve. Since 1997, Quintiq has been solving each of those challenges using a single supply chain planning and optimization software. Today, industry-leading companies across the globe rely on Quintiq software to plan and optimize workforces, logistics and production. Quintiq is part of Dassault Systèmes (Euronext Paris: #13065, DSY.PA) and has headquarters in the Netherlands and the USA, and offices around the world.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi